{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:42:26Z","timestamp":1792057346323,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH\/NCI","award":["R37CA235602"],"award-info":[{"award-number":["R37CA235602"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02059-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:24:33Z","timestamp":1751347473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"27","author":[{"given":"Ghazaleh","family":"Pourali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya S.","family":"Sherpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongliang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetunji T.","family":"Toriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2059_CR1","doi-asserted-by":"publisher","unstructured":"Giaquinto AN. et al. Breast cancer statistics 2024. CA: A Cancer Journal for Clinicians n\/a, https:\/\/doi.org\/10.3322\/caac.21863.","DOI":"10.3322\/caac.21863"},{"key":"2059_CR2","doi-asserted-by":"publisher","first-page":"e2353331","DOI":"10.1001\/jamanetworkopen.2023.53331","volume":"7","author":"S Xu","year":"2024","unstructured":"Xu S, Murtagh S, Han Y, Wan F, Toriola AT. Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. JAMA Netw Open. 2024;7:e2353331. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.53331.","journal-title":"JAMA Netw Open"},{"key":"2059_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/s1470-2045(11)70030-4","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496\u2013503. https:\/\/doi.org\/10.1016\/s1470-2045(11)70030-4.","journal-title":"Lancet Oncol"},{"key":"2059_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3322\/caac.21225","volume":"64","author":"GA Colditz","year":"2014","unstructured":"Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin. 2014;64:186\u201394. https:\/\/doi.org\/10.3322\/caac.21225.","journal-title":"CA Cancer J Clin"},{"key":"2059_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1159\/000369573","volume":"9","author":"J Stubert","year":"2014","unstructured":"Stubert J, Dieterich M, Gerber B. Medical prevention of breast cancer. Breast Care (Basel). 2014;9:391\u20136. https:\/\/doi.org\/10.1159\/000369573.","journal-title":"Breast Care (Basel)"},{"key":"2059_CR6","doi-asserted-by":"publisher","unstructured":"Fisher B. et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI: Journal of the National Cancer Institute. 1998;90:1371\u20131388, https:\/\/doi.org\/10.1093\/jnci\/90.18.1371.","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"2059_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1586\/14737140.9.1.51","volume":"9","author":"VG Vogel","year":"2009","unstructured":"Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther. 2009;9:51\u201360. https:\/\/doi.org\/10.1586\/14737140.9.1.51.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2059_CR8","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1103507.","journal-title":"N Engl J Med"},{"key":"2059_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1146\/annurev.publhealth.121208.131051","volume":"31","author":"GA Colditz","year":"2010","unstructured":"Colditz GA, Taylor PR. Prevention trials: their place in how we understand the value of prevention strategies. Annu Rev Public Health. 2010;31:105\u201320. https:\/\/doi.org\/10.1146\/annurev.publhealth.121208.131051.","journal-title":"Annu Rev Public Health"},{"key":"2059_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/jama.2019.11885","volume":"322","author":"UPST Force","year":"2019","unstructured":"Force UPST. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322:857\u201367. https:\/\/doi.org\/10.1001\/jama.2019.11885.","journal-title":"JAMA"},{"key":"2059_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","volume":"20","author":"KL Britt","year":"2020","unstructured":"Britt KL, Cuzick J, Phillips K-A. Key steps for effective breast cancer prevention. Nat Rev Cancer. 2020;20:417\u201336. https:\/\/doi.org\/10.1038\/s41568-020-0266-x.","journal-title":"Nat Rev Cancer"},{"key":"2059_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrclinonc.2013.169","volume":"10","author":"N Gronich","year":"2013","unstructured":"Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol. 2013;10:625\u201342. https:\/\/doi.org\/10.1038\/nrclinonc.2013.169.","journal-title":"Nat Rev Clin Oncol"},{"key":"2059_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1158\/1940-6207.Capr-13-0424","volume":"7","author":"S Gandini","year":"2014","unstructured":"Gandini S, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 2014;7:867\u201385. https:\/\/doi.org\/10.1158\/1940-6207.Capr-13-0424.","journal-title":"Cancer Prev Res (Phila)"},{"key":"2059_CR14","doi-asserted-by":"publisher","unstructured":"Mocellin S, Pilati P, Briarava M, & Nitti D. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials. J Natl Cancer Inst. 2016;108. https:\/\/doi.org\/10.1093\/jnci\/djv318.","DOI":"10.1093\/jnci\/djv318"},{"key":"2059_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012191.pub2","author":"S Mocellin","year":"2019","unstructured":"Mocellin S, Goodwin A, Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2019. https:\/\/doi.org\/10.1002\/14651858.CD012191.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2059_CR16","doi-asserted-by":"publisher","unstructured":"Sterne JA. C, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.). 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"2059_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Research synthesis methods. 2012;3:312\u201324.","journal-title":"Research synthesis methods"},{"key":"2059_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163\u201371.","journal-title":"J Clin Epidemiol"},{"key":"2059_CR19","unstructured":"R Core Team, R: A Language and Environment for Statistical Computing. 2023. https:\/\/www.R-project.org\/."},{"key":"2059_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","volume":"106","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, et al. netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023;106:1\u201340.","journal-title":"J Stat Softw"},{"key":"2059_CR21","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727\u201341. https:\/\/doi.org\/10.1001\/jama.295.23.joc60074.","journal-title":"JAMA"},{"key":"2059_CR22","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/s0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125\u201335. https:\/\/doi.org\/10.1016\/s0140-6736(09)60953-3.","journal-title":"Lancet"},{"key":"2059_CR23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1046\/j.1464-5491.1999.00201.x","volume":"16","author":"F Gregorio","year":"1999","unstructured":"Gregorio F, et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Med. 1999;16:1016\u201324. https:\/\/doi.org\/10.1046\/j.1464-5491.1999.00201.x.","journal-title":"Diabet Med"},{"key":"2059_CR24","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/jnci\/91.24.2102","volume":"91","author":"IM Lee","year":"1999","unstructured":"Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. \u03b2-carotene supplementation and incidence of cancer and cardiovascular disease: the Women\u2019s Health Study. J Natl Cancer Inst. 1999;91:2102\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"2059_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1006478317173","volume":"65","author":"JA Cauley","year":"2001","unstructured":"Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Breast Cancer Res Treatment. 2001;65:125\u201334. https:\/\/doi.org\/10.1023\/A:1006478317173.","journal-title":"Breast Cancer Res Treatment"},{"key":"2059_CR26","doi-asserted-by":"crossref","unstructured":"Hercberg S. et al. The SU. VI. MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Int Med. 2004;164:2335\u20132342.","DOI":"10.1001\/archinte.164.21.2335"},{"key":"2059_CR27","doi-asserted-by":"publisher","unstructured":"Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR. M CA. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Institute. 2004;96:1751-1761, https:\/\/doi.org\/10.1093\/jnci\/djh319","DOI":"10.1093\/jnci\/djh319"},{"key":"2059_CR28","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B. Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy: The Women\u2019s Health Initiative Randomized Controlled Trial. JAMA. 2004;291:1701\u201312. https:\/\/doi.org\/10.1001\/jama.291.14.1701.","journal-title":"JAMA"},{"key":"2059_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.294.1.56","volume":"294","author":"IM Lee","year":"2005","unstructured":"Lee IM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women\u2019s Health Study: a randomized controlled trial. JAMA. 2005;294:56\u201365.","journal-title":"JAMA"},{"key":"2059_CR30","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Institute. 2005;97:1652\u201362. https:\/\/doi.org\/10.1093\/jnci\/dji372.","journal-title":"J Natl Cancer Institute"},{"key":"2059_CR31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/annonc\/mdl047","volume":"17","author":"U Veronesi","year":"2006","unstructured":"Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol. 2006;17:1065\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdl047.","journal-title":"Ann Oncol"},{"key":"2059_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The N Engl J Med. 2006;355:125\u201337.","journal-title":"The N Engl J Med"},{"key":"2059_CR33","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/ajcn\/85.6.1586","volume":"85","author":"JM Lappe","year":"2007","unstructured":"Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85:1586\u201391.","journal-title":"Am J Clin Nutr"},{"key":"2059_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djk154","volume":"99","author":"U Veronesi","year":"2007","unstructured":"Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D\u2019Aiuto G, Oliviero P. Tamoxifen for the prevention of breast cancer: Late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Institute. 2007;99:727\u201337. https:\/\/doi.org\/10.1093\/jnci\/djk154.","journal-title":"J Natl Cancer Institute"},{"key":"2059_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jnci\/djk050","volume":"99","author":"TJ Powles","year":"2007","unstructured":"Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Institute. 2007;99:283\u201390. https:\/\/doi.org\/10.1093\/jnci\/djk050.","journal-title":"J Natl Cancer Institute"},{"key":"2059_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jnci\/djk049","volume":"99","author":"J Cuzick","year":"2007","unstructured":"Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Institute. 2007;99:272\u201382. https:\/\/doi.org\/10.1093\/jnci\/djk049.","journal-title":"J Natl Cancer Institute"},{"key":"2059_CR37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa0800743","volume":"359","author":"SR Cummings","year":"2008","unstructured":"Cummings SR, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697\u2013708.","journal-title":"N Engl J Med"},{"key":"2059_CR38","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/jnci\/djn360","volume":"100","author":"RT Chlebowski","year":"2008","unstructured":"Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O\u2019Sullivan MJ, Yasmeen S. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Institute. 2008;100:1581\u201391. https:\/\/doi.org\/10.1093\/jnci\/djn360.","journal-title":"J Natl Cancer Institute"},{"key":"2059_CR39","doi-asserted-by":"publisher","unstructured":"Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, Moroni SM, M F. Randomized double-blind 2 X 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol. 2009;27:3749-3756. https:\/\/doi.org\/10.1200\/JCO.2008.19.3797","DOI":"10.1200\/JCO.2008.19.3797"},{"key":"2059_CR40","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/jnci\/djq415","volume":"102","author":"AZ LaCroix","year":"2010","unstructured":"LaCroix AZ, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010;102:1706\u201315.","journal-title":"J Natl Cancer Inst"},{"key":"2059_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","volume":"3","author":"VG Vogel","year":"2010","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER. Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: Preventing breast cancer. Cancer Prevent Res. 2010;3:696\u2013706. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-10-0076.","journal-title":"Cancer Prevent Res"},{"key":"2059_CR42","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Al\u00e9s-Mart\u00ednez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1103507.","journal-title":"N Engl J Med"},{"key":"2059_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1210\/jc.2011-1309","volume":"97","author":"A Avenell","year":"2012","unstructured":"Avenell A, et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and\/or calcium (RECORD trial). J Clin Endocrinol Metab. 2012;97:614\u201322.","journal-title":"J Clin Endocrinol Metab"},{"key":"2059_CR44","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10549-012-2041-5","volume":"134","author":"TJ Powles","year":"2012","unstructured":"Powles TJ, Diem SJ, Fabian CJ, Neven P, Wickerham DL, Cox DA, Muram D, Agnusdei D, Dowsett SA. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treatment. 2012;134:299\u2013306. https:\/\/doi.org\/10.1007\/s10549-012-2041-5.","journal-title":"Breast Cancer Res Treatment"},{"key":"2059_CR45","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","volume":"30","author":"DC Allred","year":"2012","unstructured":"Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP protocol B-24. J Clin Oncol. 2012;30:1268\u201373. https:\/\/doi.org\/10.1200\/JCO.2010.34.0141.","journal-title":"J Clin Oncol"},{"key":"2059_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","volume":"159","author":"NR Cook","year":"2013","unstructured":"Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77\u201385.","journal-title":"Ann Intern Med"},{"key":"2059_CR47","doi-asserted-by":"publisher","unstructured":"DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C, Cazzaniga M, Lazzeroni M, Rotmensz N, Santillo B, & et al. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol. 2013;24:2753\u20102760. https:\/\/doi.org\/10.1093\/annonc\/mdt244","DOI":"10.1093\/annonc\/mdt244"},{"key":"2059_CR48","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.18.01779","volume":"37","author":"A DeCensi","year":"2019","unstructured":"DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Taverniti C, Pacquola MG, Falcini F, Gulisano M, Digennaro M. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37:1629\u201337. https:\/\/doi.org\/10.1200\/JCO.18.01779.","journal-title":"J Clin Oncol"},{"key":"2059_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B, Evans DG, Howell A. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. The Lancet. 2020;395:117\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(19)32955-1.","journal-title":"The Lancet"},{"key":"2059_CR50","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/01.ogx.0000723348.06789.02","volume":"75","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, Barrington W, Kuller LH, Simon MS. Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality during Long-term Follow-up of the Women\u2019s Health Initiative Randomized Clinical Trials. Obstet Gynecol Survey. 2020;75:737\u20139. https:\/\/doi.org\/10.1097\/01.ogx.0000723348.06789.02.","journal-title":"Obstet Gynecol Survey"},{"key":"2059_CR51","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. JAMA. 1998;279:1615\u201322.","journal-title":"JAMA"},{"key":"2059_CR52","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","volume":"288","author":"HA Trial","year":"2002","unstructured":"Trial HA. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998\u20133007.","journal-title":"JAMA"},{"key":"2059_CR53","doi-asserted-by":"publisher","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20\u2008536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002;360:7\u201322, https:\/\/doi.org\/10.1016\/S0140-6736(02)09327-3\n.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"2059_CR54","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bmj.326.7387.469","volume":"326","author":"DP Trivedi","year":"2003","unstructured":"Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003;326:469.","journal-title":"BMJ"},{"key":"2059_CR55","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(04)16936-5","volume":"364","author":"TE Strandberg","year":"2004","unstructured":"Strandberg TE, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). The Lancet. 2004;364:771\u20137.","journal-title":"The Lancet"},{"key":"2059_CR56","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1158\/1055-9965.EPI-11-0222","volume":"20","author":"G von Minckwitz","year":"2011","unstructured":"von Minckwitz G, Loibl S, Jackisch C, Paepke S, Nestle-Kraemling C, Lux MP, Maass N, Schmutzler R, du Bois A, Wallwiener D, Vescia S. The GISS trial: A phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer. Cancer Epidemiol Biomarkers Prevent. 2011;20:2141\u20139. https:\/\/doi.org\/10.1158\/1055-9965.EPI-11-0222.","journal-title":"Cancer Epidemiol Biomarkers Prevent"},{"key":"2059_CR57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1158\/1055-9965.EPI-17-0158","volume":"27","author":"A Howell","year":"2018","unstructured":"Howell A, Ashcroft L, Fallowfield L, Eccles DM, Eeles RA, Ward A, Brentnall AR, Dowsett M, Cuzick JM, Greenhalgh R. RAZOR: A phase II open randomized trial of screening plus goserelin and raloxifene versus screening alone in premenopausal women at increased risk of breast cancer. Cancer Epidemiol Biomarkers Prevent. 2018;27:58\u201366. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0158.","journal-title":"Cancer Epidemiol Biomarkers Prevent"},{"key":"2059_CR58","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001\u20139.","journal-title":"N Engl J Med"},{"key":"2059_CR59","doi-asserted-by":"publisher","unstructured":"Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med. 339:1349\u20131357.\u00a0https:\/\/doi.org\/10.1056\/NEJM199811053391902.","DOI":"10.1056\/NEJM199811053391902"},{"key":"2059_CR60","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The Lancet. 2002;360:1623\u201330.","journal-title":"The Lancet"},{"key":"2059_CR61","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427\u201343.","journal-title":"N Engl J Med"},{"key":"2059_CR62","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","volume":"16","author":"DF Archer","year":"2009","unstructured":"Archer DF, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009;16:1109\u201315.","journal-title":"Menopause"},{"key":"2059_CR63","doi-asserted-by":"crossref","unstructured":"Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn AR, & Perez A. Observational follow\u2010up of the PROactive study: a 6\u2010year update. Diabetes Obesity Metabol. 2014;16:63\u201374.","DOI":"10.1111\/dom.12180"},{"key":"2059_CR64","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.2147\/DMSO.S330625","volume":"14","author":"W Leng","year":"2021","unstructured":"Leng W, Pu D, Jiang J, Lei X, Wu Q, Chen B. Effect of metformin on breast density in overweight\/obese premenopausal women. Diabetes Metabol Syndrome Obes. 2021;14:4423\u201332. https:\/\/doi.org\/10.2147\/DMSO.S330625.","journal-title":"Diabetes Metabol Syndrome Obes"},{"key":"2059_CR65","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652\u201362. https:\/\/doi.org\/10.1093\/jnci\/dji372.","journal-title":"J Natl Cancer Inst"},{"key":"2059_CR66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2008.08.008","volume":"276","author":"S Wei","year":"2009","unstructured":"Wei S, Yang J, Lee SL, Kulp SK, Chen CS. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett. 2009;276:119\u201324. https:\/\/doi.org\/10.1016\/j.canlet.2008.08.008.","journal-title":"Cancer Lett"},{"key":"2059_CR67","doi-asserted-by":"publisher","first-page":"11844","DOI":"10.1038\/s41598-023-38431-z","volume":"13","author":"Y Chen","year":"2023","unstructured":"Chen Y, et al. Diabetes medications and cancer risk associations: a systematic review and meta-analysis of evidence over the past 10 years. Sci Rep. 2023;13:11844. https:\/\/doi.org\/10.1038\/s41598-023-38431-z.","journal-title":"Sci Rep"},{"key":"2059_CR68","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1634\/theoncologist.2012-0302","volume":"18","author":"C Bosetti","year":"2013","unstructured":"Bosetti C, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist. 2013;18:148\u201356. https:\/\/doi.org\/10.1634\/theoncologist.2012-0302.","journal-title":"Oncologist"},{"key":"2059_CR69","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67\u201375. https:\/\/doi.org\/10.1016\/s1470-2045(14)71171-4.","journal-title":"Lancet Oncol"},{"key":"2059_CR70","unstructured":"Network., N. C. C. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer Risk Reduction. Version 1.2025. 2025.\u00a0https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1420\u00a0"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02059-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02059-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02059-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:24:35Z","timestamp":1751347475000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02059-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2059"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02059-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}